The House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug costs and strengthen the Affordable Care Act’s health insurance marketplaces. The legislation’s drug-related provisions would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, and help decrease the time it takes for generic competitors to get to market. The ACA marketplace provisions would provide funding to expand navigator support and outreach to help consumers enroll in individual market coverage, and void a final rule that expanded short-term limited duration health plans. 
 

Related News Articles

Headline
A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The…
Headline
President Biden today urged Congress to allow Medicare to negotiate prescription drug prices and cap the amount beneficiaries pay out-of-pocket for drugs each…
Headline
Some individuals with “long COVID” may have a disability under Section 1557 of the Affordable Care Act and other civil rights laws that entitles them to…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
Fourteen leading U.S. drug companies from 2016 to 2020 spent $577 billion on stock buybacks and dividends, $56 billion more than they spent on research…
Headline
The Department of Health and Human Services today withdrew requests for proposals on ways individuals could import prescription drugs from other countries…